Your global support in Europe Over 20 years of experience ELM Pharmaceutica.

Slides:



Advertisements
Similar presentations
Background information
Advertisements

Business Development Licensing Strategic Marketing HFA-Consulting.com Pharmaceutical Business Development & Licensing Consultancy HFA provides specialist.
„Ensuring Regulatory and Pharmacovigilance Compliance“ „Ensuring Regulatory and Pharmacovigilance Compliance“
7 th Framework Programme (FP7) - Malta’s participation th January 2013 Anthea Fabri FP7 National Coordinator Malta Council for Science and.
Disclaimer The presentation is intended for educational purposes only and does not replace independent professional judgement. Statements of fact and opinions.
„Ensuring Regulatory and Pharmacovigilance Compliance“ „Ensuring Regulatory and Pharmacovigilance Compliance“
Panel themes of the International Conference “Europe against Counterfeit Medicines” G.N. Gildeeva, Deputy head of the Department of Registration of Medicines.
EDC PHARMA SERVICES Capacity. Expertise. Solutions. Technology.
ELM Farmacéutica. MEDICINAL PRODUCTS From development to marketing Development Dossier in European form Marketing authorization in UE Marketing Meetings.
Critical Success Factors for the Korean Generic and API Industry in a post FTA Environment DAVID HARDING SEOUL JUNE 28-29, 2007.
EMERGING AND RE-EMERGING INFECTIOUS DISEASES: A CONTINUOUS CHALLENGE FOR EUROPE STOA - AVIESAN Workshop June 19th 2012, European Parliament, Bruxelles.
GLOBAL REGULATORY STRATEGY CONSIDERATIONS SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES SEPTEMBER 14-17, 2008 BOSTON, MA.
Requirements of EU pharmacovigilance legislation for distributors Julia Sipos Quality Management Director Pharmacovigilance coordinator Version 03.
Conference: Generic Drugs in Turkey and the EU THE PORTUGUESE MODEL FOR STIMULATING GENERIC COMPETITION IN THE EU June 2, 2005, Ankara, Turkey Rui Santos.
An Introduction to H IPS HealthCare Infrastructure Professional Services Leading to healthcare. accreditation.
Pharma.be The Initiative to Promote Clinical Trials in Belgium Key Performance Indicators: Impact on Clinical Research of European Legislation Square –
1 Establishing a Pharmacovigilance Centre Sten Olsson the Uppsala Monitoring Centre.
Center for Veterinary Medicine (CVM) RECALLS.  21 CFR 7.40 provides guidance on the policy, procedures, and industry responsibilities for recalls. 
Benefits of a strong collaboration with patient groups at national and EU level Susanna Palkonen, Director European Federation.
FOOTPRINTS Organisations are continuously looking for Business, Partners, Alliances and Talented People Organisations are continuously looking for Opportunities.
„Ensuring Regulatory and Pharmacovigilance Compliance“ „Ensuring Regulatory and Pharmacovigilance Compliance“
Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.
INTRODUCTION TO RA.
PRODUCT TRANSFER.
SAHPRA proposals Nov 2009 A GLIMPSE OF WHAT SAHPRA IS INTENDED TO BECOME KEY PROPOSALS FOR SAHPRA NOVEMBER 2009 DR NICHOLAS CRISP.
MEDICAL experts INDUSTRY Some of our clients. Pharmaceutical companies, manufacturers of medical and surgical devices, clinical research organizations,
ACCREDITED CONSULTANTS PVT LTD. (ACPL) WELCOMES YOU Your PHARMACOVIGILANCE PARTNER.
International Consulting Data Sheet. 1 Program Management for International Headquarters (IHQ) Why does a company go International ? Increase of business.
BIC Group Ltd. Presentation of company Žilina We are......consulting company specialising primarily in practical assistence in the field of.
Directorate General for Enterprise and Industry European Commission The New Legislative Framework - Market Surveillance UNECE “MARS” Group meeting Bratislava,
The ERA-NET TRANSCAN-2, in continuity with the preceding ERA-NET TRANSCAN, aims at linking translational cancer research funding programmes in 15 Member.
LICENSING PRESENTATION September 2013
Project funded by the Spanish Ministry of Science and Innovation and the European Regional Development Fund PROGRESS REPORT SEPTEMBER 2009 Brussels, 22.
GMP- A Regulatory Perspective. Regulatory Perspective in entering Global Pharma Markets.
Transatlantic Administrative Simplification Workshop European Preparatory Roundtable Suzette Kox EGA Senior Director Scientific Affairs.
Process mapping of registration to reimbursement for new pharmaceuticals in UK.
Board Development Building Partnerships and Planning for the Future Joey Wallace RESNA/NATTAP February 12, 2008.
128/02/2011 Confidential Who is Alcimed ? ALCIMED is a European consulting company specialized in Life Sciences/Healthcare and Chemicals, founded in 1993.
VICH General Principles and current update of VICH Outreach Forum activity 1.
1 CHALLENGES IN REGULATING QUALITY AND RATIONAL USE OF ANTIBIOTICS ALLIANCE FOR THE PRUDENT USE OF ANTIBIOTICS: INAGURAL MEETING COURTYARD.
China EU Pharmaceutical Forum
Prepared by: Imon Rahman Lecturer Department of Pharmacy BRAC University.
BioEnergy Sustaining The Future 2 BESTF2 Briefing Event 11 th December 2013 Dr Megan Cooper, BESTF co-ordinator.
1 Pharmacovigilance & the New National Adverse Drug Reaction (ADR) Reporting System Michael Bonett, Quality Assessor Post-Licensing Directorate Medicines.
Slide 1 The contribution of a world-class regulatory environment to the future of the industry in Ireland Pat O’Mahony Chief Executive, Irish Medicines.
Knowledge Transfer Accelerating Innovation. slide 1 The Knowledge Transfer Group at the HR Induction Program (session II) 9 th June 2011 Giovanni Anelli.
Regulatory Intelligence for the Emerging Markets Lisa Rysso-DeMaggio President, RAQUELIAN Consulting DIA Regulatory Intelligence Working Group, 10 Sep.
1 PHARMACOVIGILANCE & THE NATIONAL ADVERSE DRUG REACTION (ADR) REPORTING SYSTEM Sarah Spiteri Post-Licensing Directorate Medicines Authority.
ICORD 2006 Kerstin Westermark Md, PhD, Assoc. prof. COMP Chairperson.
Regulatory Updates Health Sciences Authority Singapore
POST APPROVAL CHANGE MANAGEMENT PROTOCOLS IN THE EUROPEAN UNION
A capacity building programme for patient representatives
Information on Medicinal Products
M&A GROUP.
Completing the cycle of innovation in Spain and LATAM
OUS Data: What does the CE Mark Really Mean?
TAIEX, Istanbul, April 19th, 2011
1888 Press Release - Spine Care Technologies Inc. and mdi Consultants Inc. Announce Strategic Alliance
Helen Lee, European Commission
PharmDr. Ján Mazag, director, State Institute for Drug Control
AGRICULTURAL & VETERINARY CHEMICALS REGULATION IN AUSTRALIA
The importance of dialogue between regulators
Beyond Academia.
Innovative Medicines Initiative:
Introduction to TransCelerate
Get the right expertise for your business? Know how
EU GATEWAY TO KOREA Facilitating long-lasting business collaborations
Pharmacovigilance updates
EUnetHTA Assembly May 2018.
Process mapping of registration to reimbursement for new pharmaceuticals in UK Description: A systematic methodology was developed in order to create the.
Presentation transcript:

your global support in Europe Over 20 years of experience ELM Pharmaceutica

Consultancy company established in 1995 and set up by a multidisciplinary active team of professionals with over 20 years of experience in bio-pharmaceutical industry. Provides services from early development, best regulatory strategy up to marketing and beyond to companies wishing to launch medicinal their products in EU market.

ELM has the required legal authorisation and organisation in-house to act as your EC company, saving initial unnecessary costs in a cost efficient and timely way. ELM Pharmaceutica

Development Dossier in European form Marketing authorization in UE Marketing Strategic application and tracking Price and reimbursement Registration dossier and European legislation Transfer/facilitati on companies: Import Distributor Manufacturer Pharmacovigilance Promotion control Clinical-preclinical trials/CMC studies Life cycle maintenance Manufacturing plant EU authorisation Advice, Coordinate, Manage, Facilitate: From Development to Marketing Internally Through companies and research centres

Multidisciplinary team having outstanding experience in: Business development Management and strategic consulting Clinical, non clinical, CMC and PhV requirements for final EU authorisation LATAM pharmaceutical market EU regulatory and legal activities through a regulatory website Regulatory policy HOW Our team: our strength Regulatory Pharmacovigilance Carla Besó + EU Development Jordi Ruiz External relations Latam Countries Xavi Perez Elisabeth Lopez Business strategy

 A long term detailed planning  Early definition of deliverable quality and efficacy criteria suitable for EMA/FDA approval  Large experience with EU regulatory agencies of drugs, medicinal food supplements and medical devices  Large experience in project coordination  Commitment to success  Connected to EU research and development centers  Large experience in EU national and transnational studies  Areas of expertise Life sciences (bio-pharmacy, veterinary science, cosmetics, nutrition, medical and environmental devices) Early detection kits development HOW: A strong network

Abbcn Developmen t of IVD ELM Pharmaceutica Development regulatory/ EU approval Method ex Lorien MAH Enoc Liposomal develop/ production Liposomed developments ELM lifescience: A strong network

Development studies We have contacts and experience with public Universities, Hospitals and private centres within Europe to perform clinical, preclinical, quality control analysis and characterisation of actives according to EU legislation in a cost efficient and timely way. A tailored made service that allows client to decide its degree of participation. Areas of activity: advice, coordination and managing

Regulatory activities Insight the company and through a regulatory web around Europe From due diligences of registration dossiers, manufacturing plant authorisation, European registration procedures (MRP, DCP, centralised or national), Marketing authorisation application, scientific advice meetings and other Agency contacts to price and reimbursment. Areas of activity: advice, coordination and managing

Pharmacovigilance Authorised by Spanish Agency and audited by our clients we can take over pharmacovigilance responsibilties, carrying out all pharmacovigilance activities in compliance with UE and in close relation with MAH requirements.

Business enhancing Identification of potential business partners from manufacturing transfer or import- batch release regulatorily necessary for commercialisation in EU, to distributors or wholesalers, licencees…..

From small start up companies to big pharmas wanting to enter EU market Our clients usa Local Responsible/MAH Due diligence Pharmacovigilance Bioequivalence Pharmaceutical development Bioequivalence studies monitoring and coordination Clinical metanalysis Scientific advices Medical writing Manufacturing plant EU authorisation Submission application Most of our clients are long term CNCE INNOVACION SL

Contact: ELM Farmacéutica Valencia 231, Ático 2ª Barcelona Phone: Fax: